Jorge Villacian | Compound Development Leader
Johnson & Johnson Innovation

Jorge Villacian, Compound Development Leader, Johnson & Johnson Innovation

Jorge is the Compound Development Leader for CD388 at Janssen R&D, where he has led the Janssen team in collaboration with Cidara Therapeutics to advance this compound through clinical development. Jorge has held several positions since joining Johnson and Johnson in 2006, including Chief Medical Officer of the Janssen Diagnostics organization, where he and his team developed and managed global research and development collaborations for a variety of diagnostic and companion diagnostic programs in different Therapeutic Areas at Janssen. Before joining J&J, he led Phase 3 development studies for anti-HIV treatments at Boehringer Ingelheim. Jorge has also served on steering and advisory committees concerning HIV and antimicrobial resistance and in multiple EU-funded projects on rapid diagnostic test development and adoption, as well as pandemic preparedness. His clinical infectious diseases experience includes working as Consultant Physician in Micronesia and later in Singapore at the Communicable Diseases Center where he played a significant role in the management of the 2003 SARS outbreak.
Jorge received his M.D. from the National Autonomous University in Mexico City, trained at Mount Sinai Medical Center in Miami and the Mayo Clinic in Rochester and is Board Certified in Internal Medicine and Infectious Diseases.


Day 1 - November 28 @ 13:50

Development of Cloudbreak Drug-FC conjugates for the prevention of seasonal influenza

last published: 02/Jan/24 12:15 GMT

back to speakers